ArticleLeukemia2019

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Donia M Moujalled et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.